Dr. Mehmet Oz, Centers for Medicare and Medicaid Services (CMS) administrator, will host the White House press briefing on Tuesday, becoming the latest Trump administration official to fill in for press secretary Karoline Leavitt while she is on maternity leave. Oz follows Secretary of State Marco Rubio, Vice President JD Vance, and Treasury Secretary Scott...
OMAHA, Neb. (AP) — Five of the 18 American cruise ship passengers who have been staying at a national quarantine facility in Nebraska after being exposed to hantavirus are going home, U.S. health officials said Monday. The five people will complete their monitoring at home after remaining symptom-free and meeting criteria for monitoring outside the...
The Family and Medical Leave Act gives eligible employees up to 12 weeks of job-protected leave for caregiving. But the federal policy has noteworthy limitations. The HealthQ team explains.
A decade ago, Michigan had high rates of parents not vaccinating their children, so it required them to attend an in-person education class to get an exemption. It worked — until things got ugly.
France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a revenue growth strategy in oncology and neurology. The deal brings an Edgewise drug in clinical development for two rare neuromuscular disorders with limited treatment options. The post Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics appeared first on MedCity News .
Eli Lilly has told more than 1,000 hospitals participating in the 340B drug discount program to submit claims data over the next five days — or lose price breaks.
With no licensed vaccines available to protect against the Ebola virus currently spreading in the Congo, efforts are underway to fast-track development of at least three vaccines.
(MedPage Today) -- CHICAGO -- Patients who skipped maintenance therapy after a complete response to upfront treatment with a PD-1 inhibitor lived just as long as those who had 3 years of maintenance, data from a cohort study that compared nonsurgical...
(MedPage Today) -- Standard-dose tenecteplase (TNKase) beat low-dose alteplase as a bridge to stroke thrombectomy in bleeding-prone patients, a Japanese trial found. Early reperfusion outcomes significantly favored patients who received tenecteplase...